



Janssen

Kaylynn Callister

HR Leader Oncology, Janssen Diagnostics, Discovery Sciences




Today's Agenda

Goal is to help you become aware of what we do; who we are; and what we believe in

- Introductions
- Intro to J&J and Janssen
- Panel of PhD employees
- Q&A and Networking

Our History

What year was Johnson & Johnson founded?



Dr. Joseph Lister



- <https://www.youtube.com/watch?v=r4-5OrdtXpI>

Our Credo Drives Our Success

“I am resolute in my determination to keep Our Credo as the foundation of Johnson & Johnson. Our Credo has long been – and must continue to be – the defining feature of our organization, because it reflects our core value system, our beliefs and our aspirations.”

–Alex Gorsky



The logo features the number '100' in a large, bold, blue font above the letters 'COM' in a smaller, bold, blue font. The text is set against a white background with a blue border. The entire logo is positioned on a yellow background with radiating lines.

World's Most Respected Companies

The financial weekly Barron's conducts an annual survey of institutional investors, rating the 100 largest public corporations (based on market capitalization) in order of the respect they have garnered from these institutions. Johnson & Johnson ranked 11th this year and has been included on this list since its inception eight years ago.

Top Companies for Women Executives

The National Association for Female Executives selected Johnson & Johnson to the Top 50 Companies for Women Executives list in 2015.

FTSE4Good Index

Johnson & Johnson has been independently assessed according to FTSE4Good criteria and has met requirements to be part of the index. The designation identifies companies that meet globally recognized corporate responsibility standards.

It was launched 28 years ago and focuses on areas such as environmental, social and elder care, among others.

Dow Jones Sustainability Index, North America

Johnson & Johnson stock has been included in this index since 2000. The DJSI family follows a best-in-class approach to identify industry leaders.

The index is a global benchmark for corporate sustainability and leadership.

U.S. Hispanic Chamber of Commerce

Johnson & Johnson was recognized as a U.S. Hispanic Chamber of Commerce Million Dollar Club member for the 6th consecutive year, a recognition provided to companies that invest a minimum of \$25 million in spend with Hispanic-owned business enterprises.

The club is a national organization of leading U.S. companies.

Best Global Green Brands

Johnson & Johnson was ranked number 12 by Interbrand's 2014 Best Global Green Brands report.

The report recognizes brands that are committed to environmental, social and governance issues and are committed to their customers.

Global 100

Johnson & Johnson ranked 18th by Corporate Knights in the 2015 Index.

Corporate Responsibility Magazine 100 Best Corporate Citizens

Johnson & Johnson ranked 3rd in the 2015 Index.

The magazine is an annual publication that recognizes the world's most admired and respected companies.


Newsweek Green Rankings

Johnson & Johnson placed 17th in the U.S. and 23rd in the Global rankings.

In 2015, Johnson & Johnson ranked number 5 on this survey. The RQ focuses on six areas that influence reputation and consumer behavior: social responsibility, emotional appeal, financial performance, products and services, vision and leadership, and workplace environment.

About the Company

BUSINESS STRUCTURE



About the Company

BUSINESS STRUCTURE – SEGMENTS

- **Consumer** – Products marketed to the general public and sold both to retail outlets and distributors.
- **Pharmaceuticals** – Products distributed directly to retailers, wholesalers, and health care professionals for prescription use.
- **Medical Devices** – Products distributed to wholesalers, hospitals, and retailers used principally in the professional field by physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics.

Pharmaceuticals

- Therapeutic Areas
 - Immunology
 - Neuroscience
 - Infectious Diseases/
Vaccines
 - Oncology
 - Cardiovascular &
Metabolism/Other

Medical Devices

- Vision Care/ Diabetes
- Global Surgery
 - Surgical Care
 - Specialty Surgery
 - Infection Prevention
 - Cardiovascular Care
- Global Orthopedics
- Diagnostics

Consumer

- Baby
- Skin Care
- Oral care
- Women's Health
- Wound Care
- OTC/Nutritionals



"Patients are waiting"

Dr. Paul Janssen

What are some of the original drug discoveries Dr. Paul Janssen made?



© Janssen Pharmaceutica, 20

Our Vision

To eliminate disease through developing highly innovative medical solutions for people around the world



The Global Pharmaceuticals Market...



Total market
reached \$1 Trillion
in 2014¹

Specialty
medicines drove
~38% of 2014
total market
growth¹

~3% 2014-2019
Market CAGR for
branded products²

A Significant Opportunity for Growth

1. IMS Market Prognosis, Sept. 2014 & Global Outlook for Medicines Through 2018 report, Nov. 2018: IMS Institute for Health Informatics.

2. May 2015 IMS Institute of Health Informatics analysis of Market Prognosis data; 2-4% CAGR forecast for 24 key countries, including EU G5, Canada, Japan and United States.

Janssen – Creating Value Through Innovation

- Leader in productivity, FDA approvals, breakthrough designations
- 14 new products since 2009
- Most FDA approvals 2009-2014
- One of the fastest growing top-ten pharmaceutical companies
- Most admired pharmaceutical company

End-to-End Therapeutic Areas Drive Success

Cardiovascular
& Metabolism

Immunology

Neuroscience

Infectious Diseases
& Vaccines

Oncology



Disease Area Strongholds

Biotech-like Teams within the Therapeutic Areas

- Concentrate R&D investment in high-priority assets
- Goal is to consistently deliver differentiated products to patients
- Understand basis of disease and prioritize key pathways and targets in context
- Build or acquire best assets
- Appreciate importance of targets in context
- Leads to investment in assets with higher success rates

Innovation Across Therapeutic Areas

More Than 10 NME Filings and 40 LE Filings Planned 2015-2019

ONCOLOGY	IMMUNOLOGY	NEUROSCIENCE	INFECTIOUS DISEASES & VACCINES	CARDIOVASCULAR & METABOLISM	
<p>Daratumumab</p> <ul style="list-style-type: none"> Multiple myeloma (MM) double refractory Relapsed refractory MM Frontline MM (non-transplant) Frontline MM (transplant) <p>JNJ-927 (ARN-509)</p> <ul style="list-style-type: none"> Pre-metastatic prostate cancer Chemo-naïve prostate cancer (ZYTIGA® combo) <p>JNJ-493 (FGFRi kinase inhibitor)</p> <ul style="list-style-type: none"> Urothelial cancer <p>Imetelstat</p> <ul style="list-style-type: none"> Myelofibrosis relapse/refractory MDS low/intermediate risk 	<p>IMBRUVICA®</p> <ul style="list-style-type: none"> CLL 2nd line combo CLL (elderly/unfit) frontline single agent CLL (young/fit) frontline combo CLL frontline combo with GA101 Mantle cell lymphoma (MCL) relapsed (EU) MCL frontline transplant ineligible Follicular lymphoma relapsed refractory DLBCL frontline combo <p>YONDELIS®</p> <ul style="list-style-type: none"> Soft tissue sarcoma* Relapsed ovarian cancer (US) <p>ZYTIGA®</p> <ul style="list-style-type: none"> Hormone-naïve metastatic prostate cancer (EU) 	<p>Guselkumab</p> <ul style="list-style-type: none"> Psoriasis <p>Sirukumab</p> <ul style="list-style-type: none"> Rheumatoid arthritis <p>STELARA®</p> <ul style="list-style-type: none"> Pediatric psoriasis* (EU) Crohn's disease Ankylosing spondylitis Nr-Axial SpA Ulcerative colitis <p>SIMPONI® / SIMPONI® ARIA®</p> <ul style="list-style-type: none"> Nr-Axial SpA, SC (EU)* PSA, IV (US) AS, IV (US) JIA, IV formulation (US) Pediatric UC, SC JIA, SC (EU) 	<p>Fulranumab</p> <ul style="list-style-type: none"> Osteoarthritis pain <p>Esketamine</p> <ul style="list-style-type: none"> Treatment-resistant depression Major depressive disorder at imminent risk for suicide <p>JNJ-922 (Orexin-2 antagonist)</p> <ul style="list-style-type: none"> Primary insomnia 	<p>Monovalent Ebola</p> <ul style="list-style-type: none"> Vaccine regimen <p>JNJ-872 (VX-787)</p> <ul style="list-style-type: none"> Influenza A <p>AL-8176</p> <ul style="list-style-type: none"> RSV infection <p>AL-335</p> <ul style="list-style-type: none"> HCV <p>PREZISTA®</p> <ul style="list-style-type: none"> HIV with STR C/F/TAF <p>EDURANT®</p> <ul style="list-style-type: none"> Pediatric HIV* HIV STR with F/TAF HIV STR with dolutegravir HIV long acting maintenance therapy <p>SIRTURO®</p> <ul style="list-style-type: none"> Pediatric TB 	<p>INVOKANA®</p> <ul style="list-style-type: none"> FDC with metformin extended release (XR), including initial therapy (US) Initial therapy with FDC with metformin immediate release (US) Type 1 diabetes mellitus FDC with phentermine for obesity <p>XARELTO® (US)</p> <ul style="list-style-type: none"> Congestive heart failure Embolic stroke of undetermined source (ESUS) Peripheral arterial disease Medically ill Pediatric VTE

* In registration

New Molecular Entities

Line Extensions

NME Filings Anticipated by 2019 Each With \$1B+ Potential¹

COMPOUND	ANTICIPATED FILING
Daratumumab* Multiple myeloma double refractory	2015
Sirukumab Rheumatoid arthritis	2016
Guselkumab Psoriasis	2016
JNJ-927 (ARN-509) Pre-metastatic prostate	2017
Imetelstat Myelofibrosis relapse refractory	2017
JNJ-493 (FGFRi kinase inhibitor) Urothelial cancer	2018
Esketamine* Treatment-resistant depression	2018
AL-8176 Respiratory syncytial virus infection	2018
Fulranumab Osteoarthritis pain	2019
JNJ-872 (VX-787) Influenza A	2019
JNJ-922 (Orexin-2 antagonist) Primary insomnia	2019
AL-335 HCV	2019


1. Peak non-risk adjusted sales, including partner sales, where applicable.

* Breakthrough Therapy Designation.

Focused, Seamless R&D

- Responsible for discovery, clinical development through launch and life cycle management
- Promotes efficient phase transitions
- Focused on high-priority disease areas that address major unmet needs

Top Ten Causes of Death Globally¹



1. WHO Disability-Adjusted Life Years (DALYs) 2000-2012 World Score by Cause.


Huge Medical Need

27,000,000

The number of new cancer cases
expected globally by 2030.

Internal Scientific Strengths


Augments Our External Innovation Strategy



Internal Strength and External Collaborations

An Elegant Mix

- J&J Innovation Centers establish presence in major research hubs
- J&J Innovation-JLABS incubators create strategic relationships
- J&J Innovation-Janssen Business Development focused on late-stage opportunities
- J&J Innovation-JJDC adds strategic investments



Envisioning a World without Disease

To Sustain Long-term Growth

- Janssen Human Microbiome Institute
- Janssen Prevention Center
- Disease Interception Accelerator



R&D Productivity Second to None

Cumulative Sales of Brands Launched from 2009 to 2014

RANK	COMPANY	(\$MM)
1	<i>Johnson & Johnson</i>	18,715
2	Gilead Sciences	13,414
3	Novartis	7,490
4	Biogen Idec Corp	6,308
5	Boehringer Ingelheim	6,477
6	Pfizer	6,264
7	Actavis US	5,977
8	Sanofi Aventis	5,795
9	Takeda	5,392
10	Novo Nordisk	5,191
	All brands launched since 2009	130,057

Source: IMS Health, National Sales Perspectives, Dec 2014.

Recognized for Sustained Innovation

IDEA PHARMA

Productive Innovation Index 2015

1	<i>Johnson & Johnson</i>	#1 for 3 YEARS
2	Gilead	
3	Novartis	
4	Merck	
5	Roche	
6	Biogen Idec	
7	Amgen	
8	Celgene	
9	Bayer	
10	Boehringer Ingelheim	

Fortune Magazine's
THE WORLDS MOST ADMIRED COMPANIES® LIST 2015
Two years in a row!

“ Seeing J&J leading the index once again further secures its stance as a true innovator in the market. ”

Mike Rea, CEO, IDEA

Our Oncology Strategy Has Resulted in Remarkable Success

- #4 Oncology company globally based on WW sales
 - Grew ~2x as fast as the average top 10 player since 2009
- Launched 3 new drugs in 4 years
- Expanded clinical portfolio dramatically
 - 27 Phase 3 trials ongoing or planned by year's end
- Among the industry leaders in hematologic malignancies and prostate cancer
- Built world-class immuno-oncology capabilities

Sources: GBI Oncology analysis: EvaluatePharma WW annual sales, Oncology market by therapeutic category (supportive care and preventative vaccines excluded).

"Patients are waiting"

Dr. Paul Janssen



© Janssen Pharmaceutica, 20

Introduction to our Panel

3-4pm

4-5pm Q&A Networking

Name	Title	Department	Email
Naushad Islam	Sr. Director, Global Regulatory	Global Regulatory Organization	nislam@its.jnj.com
Anne Vosatka	VP, Compound Development Team Leader	Cardiovascular & Metabolics	avosatka@its.jnj.com
John Fastenau	Team Leader, Real World Evidence	Real World Evidence	jfastena@its.jnj.com
Daniel Weinstock	Sr. Director, Immunopathology Toxicology	Janssen Biotherapeutics	dweinsto@its.jnj.com
Homer Adams	Sr. Scientist	Oncology	hadamsii@its.jnj.com
Brent Rupnow	Director, Prostate Discovery	Oncology	brupnow@its.jnj.com
Nishan Sengupta	Global Market Access Leader	Oncology	nsengupt@its.jnj.com
Doris Forestal	Director, TA Head Global Labeling Oncology/CVM	Oncology/CVM	dforestal@its.jnj.com
Samantha Allen	Sr. Scientist	Screening	sallen37@its.jnj.com